Should the U.S. Prohibit Reproductive Cloning?
By Tim Sandle,
Digital Journal
| 04. 18. 2014
[Quotes CGS's Marcy Darnovsky]
Untitled Document
Researchers have produced stem cell lines using somatic cell nuclear transfer (SCNT) from cells, making human reproductive cloning more technically feasible. Is this a good idea?
Not according to Marcy Darnovsky, PhD, executive director of the Center for Genetics and Society, a public interest organization based in Berkeley, California.
Talking to the Digital Journal, Darnovsky said: "No one wants to wake up to headlines that a rogue fertility doctor or scientist initiated a pregnancy with a cloned human embryo."
The Center for Genetics and Society (CGS) is a non-profit public affairs and policy advocacy organization working to encourage responsible uses and effective societal governance of human genetic and reproductive biotechnologies.
The basis of Darnovsky's concern relates to a study
published in the journal
Cell Stem Cell. In the journal, researchers report that they have produced stem cell lines using somatic cell nuclear transfer (SCNT) from cells taken from two adult men. The aim of this work is to produce patient-specific stem cells for medical treatments. But unlike induced pluripotent stem cells, which can also be patient-specific, SCNT...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...